Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets recover
Wed, 28 Aug 01:30 pm

Indian equity markets have made some recovery in the last two hours of trade, however, they continue to trade below the dotted line. Barring stocks from IT sector all the sectors are witnessing selling pressure. PSU and realty stocks are leading among the pack of losers.

BSE-Sensex is down by 66 points and NSE-Nifty is trading down by 33 points. While BSE Mid Cap is trading down by 1.76%, BSE Small Cap index is trading down by 1.22%. The rupee is trading at 68.05 to the US dollar.

Majority of the automobile stocks are trading in the red with Mahindra & Mahindra and Escorts being the biggest losers. As per a leading financial daily, passenger car major Maruti Suzuki has deferred the commissioning of its Gujarat plant beyond FY16 in the light of the severe slowdown in automobile sales. Reportedly, the company has not commenced industrial construction work at the site. The company had planned an initial investment of Rs 40 bn to set up a manufacturing plant near Mehsana in Gujarat. The plant with a capacity of 2.5 lakh units was to go on-stream by 2015-16. Maruti Suzuki has not specified when it would commence work at the unit. The company has said that it is analyzing the current slowdown in the domestic market before arriving at any decision on new facilities in the state of Gujarat. The stock of Maruti Suzuki is currently down by 2.4%.

Most of the Indian pharma Stocks are trading in red, with Dishman Ltd and Elder pharma leading the pack of losers. As per the financial daily, Delhi court has extended the relief period on relabeling of their existing stock as per the new pricing policy. Some of the companies including Sun pharmaceuticals and Cipla Ltd> have been given an extension to replace their inventories with the new price labels. The next hearing on this case is now scheduled on September 23 2013. The two companies along with various other pharma companies like; Lupin Ltd, Wockhardt, Alembic pharma, and so on had challenged the government on specific provision under Drug Price Control Order 2013. As per this order, the companies have to compulsorily change the label to revised prices within 45 days of the price notification. This extension would provide additional time to the companies to sell the drugs on the old price, which are likely to be higher than the revised prices given by the regulators.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets recover". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.